Literature DB >> 11498597

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.

R de la Fuente-Fernández1, T J Ruth, V Sossi, M Schulzer, D B Calne, A J Stoessl.   

Abstract

The power of placebos has long been recognized for improving numerous medical conditions such as Parkinson's disease (PD). Little is known, however, about the mechanism underlying the placebo effect. Using the ability of endogenous dopamine to compete for [11C]raclopride binding as measured by positron emission tomography, we provide in vivo evidence for substantial release of endogenous dopamine in the striatum of PD patients in response to placebo. Our findings indicate that the placebo effect in PD is powerful and is mediated through activation of the damaged nigrostriatal dopamine system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498597     DOI: 10.1126/science.1060937

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  191 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine?

Authors:  Samuel Vozeh
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 3.  The biochemical bases of the placebo effect.

Authors:  Raúl de la Fuente-Fernández; A Jon Stoessl
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

Review 4.  The use of the placebo effect in clinical medicine--ethical blunder or ethical imperative?

Authors:  Nikola Biller-Andorno
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

Review 5.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

6.  Individual expectation: an overlooked, but pertinent, factor in the treatment of individuals experiencing musculoskeletal pain.

Authors:  Joel E Bialosky; Mark D Bishop; Joshua A Cleland
Journal:  Phys Ther       Date:  2010-06-30

7.  Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors.

Authors:  Fabrizio Benedetti; Martina Amanzio; Wilma Thoen
Journal:  Psychopharmacology (Berl)       Date:  2010-10-08       Impact factor: 4.530

8.  Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans.

Authors:  Irene Tracey
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

Review 9.  Placebo response: a consideration of its role in therapeutics.

Authors:  Richard L Kradin
Journal:  Curr Psychiatry Rep       Date:  2011-02       Impact factor: 5.285

10.  An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease.

Authors:  Charles M Epstein; Marian L Evatt; Agnes Funk; Lhys Girard-Siqueira; Nichole Lupei; Larisa Slaughter; Saima Athar; Joanne Green; William McDonald; Mahlon R DeLong
Journal:  Clin Neurophysiol       Date:  2007-08-21       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.